Clinical Trial Update: Mirdametinib in Patients With Advanced NF1-mutant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Mirdametinib in patients with advanced or metastatic NF1-mutant melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Mirdametinib (mirdametinib)

Snippet

Sponsor: Kevin Kim, MD | Conditions: Advanced Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Status: RECRUITING